Intravenous Interferon β-1a for Severe ARDS

To the Editor Dr Ranieri and colleagues found that intravenous interferon (IFN) β-1a administered for 6 days, compared with placebo, did not result in significant improvement in a composite score that included death and ventilator-free days over a total of 28 days in patients with acute respiratory distress syndrome (ARDS). Some important issues remain to be discussed.
Source: JAMA - Category: General Medicine Source Type: research